The 17-ICML abstract submission will open in December 2022. Submission will be possible until Wednesday, March 15, 2023, 17:59 CET.
Abstracts can be related to all aspects of the biology and treatment of lymphoid neoplasms, including CLL and multiple myeloma, as detailed in the “Abstract categories list” (see below).
Except for Encore Abstracts (please see pertinent paragraph), abstracts must present original scientific material unpublished at the time of the abstract submission deadline and should not be published before the 17-ICML. Updated analyses must substantially differ from previous publications, adding novel information worthy of being presented.
The submission of an abstract does not constitute registration to the 17-ICML.
Presenters of abstracts selected for oral and poster presentation must register to attend the meeting. In-person participation is required and no reimbursement for travel and/or hotel expenses is provided.
|Opening of the abstract submission||December 15, 2022|
|Deadline of regular abstract
and Late-breaking abstract covering
|March 15, 2023 (17:59 CET)|
|Outcome notification to first authors||by May 2, 2023|
|Late-breaking abstract submission deadline||May 25, 2023 (17:59 CEST)|
|Outcome notification to LBA first authors||TBD|
|Online publication of 17-ICML Abstract Book
(end of embargo on data included in accepted abstracts,
except for LBA and Encore Abstracts)
|June 9, 2023 (23:59 CEST)|
|Release of LBA||TBD|
Regular abstracts will be evaluated and selected for oral presentation (general sessions and “Focus on…” sessions), poster presentation and/or for inclusion in the 17-ICML Abstract Book.
Notification of the regular abstract evaluation results (acceptance for oral or poster presentation, inclusion in the 17-ICML Abstract Book or rejection) will be sent by e-mail to the first author by Tuesday, May 2, 2023.
Early registration fee applies to presenters of abstracts selected for oral and poster.
The authors of ICML abstracts retain the copyright of their abstracts when published in the Abstract Book, supplement to “Hematological Oncology” (John Wiley and Sons, Inc.).
The first authors and co-authors can reuse their abstract, i.e. they have permission to:
- reprint the abstract in collections of the co-authors’ writing
- present the abstract orally in its entirety
- use the article, figures and tables, in theses, dissertations and future works
- reproduce the abstract for use in courses they are teaching
- distribute copies of the abstract to colleagues, for non-commercial purposes only
- post a copy of the abstract on the co-author’s personal and/or institution website, provided that a hyperlink to the abstract on Wiley website is included
- translate the abstract to local language for reprinting
Inclusion of the reference “This abstract is included in the 17-ICML Abstract Book, (URL to abstract publication)” is appreciated.
If an abstract has been published or previously submitted to other conferences where copyright restrictions apply, authors should ensure that they have permission to reuse the abstract for print and online publication in the ICML Abstract Book and include any references applicable to previous or in progress publication.
All accepted abstracts will be included in the Abstract Book, supplement to “Hematological Oncology” (John Wiley and Sons, Inc.), published online on Wiley Online Library on June 9 (23:59 CEST). Prior to this date, submitted abstracts (except for Encore abstracts) must be treated as confidential by the 17-ICML Organizing Committee, Advisory Board, reviewers, as well as the first author, co-authors and research sponsors.
The Program of the 17-ICML and the titles of the abstracts selected for presentation (oral and poster) will be published online on this website about 4-6 weeks before the Conference (exact date TBD).
Data and information included in all accepted abstracts (except Encore abstracts) are under embargo until June 9 (23:59 CEST).
Data and information beyond what is included in the accepted abstracts (e.g. full data sets, articles), may only be made public at the beginning of the official program session during which the study is presented.
If a company is required to disclose data or other information from a confidential abstract before the public release, the press release must include a qualitative summary of the abstract avoiding quantitative information and must indicate that the data have been submitted to 17-ICML for presentation during the event and/or publication in the Abstract Book. The company must send a copy of the press release to email@example.com for reference.
During the online abstract submission, the following information will be required:
- Presenter’s complete contact details:
First and middle name, surname, institution, department, mailing address, city and country, telephone number and e-mail address, for urgency correspondence and future notification on the abstract evaluation outcome.
- Acceptance of the abstract submission policy and regulations - also on behalf of the co-authors - in particular:
- release of the permission to include the abstract, if selected, in the 17-ICML Abstract Book, published electronically in the Wiley Online Library by John Wiley and Sons, Inc. as a supplement to “Hematological Oncology”;
- release of the permission to live-stream, record for multimedia coverage and include his/her presentation in the 17-ICML on-demand resources;
- disclosure of the conflict of interest;
- no prior publication of the same abstract, except for Encore abstracts (see below), and no inclusion of the abstract in the scientific material provided during the 17-ICML satellite symposia (the company organizing the satellite symposium undertakes to verify that the abstracts included in the symposium material are formally different from those submitted at 17-ICML);
- withdrawal policy:
- all abstracts that have been selected for oral or poster presentation must be presented and will be included in the 17-ICML Abstract Book;
- abstracts selected for publication only will be included in the 17-ICML Abstract Book, unless explicitly indicated during the submission (ticking the Withdrawal check-box).
No abstract withdrawal request will be accepted if received after the deadline.
- Co-authors’ first and middle name initials, surname, institution, department, city and country, e-mail address.
- Preference of presentation (no remote presentation will be possible)
- oral presentation (general sessions and “Focus on…” sessions)
- poster presentation
- no preference
The Organizing Committee reserves the right to conclusively decide the presentation format, based on the evaluation results and the Scientific Program structure.
- Ongoing trials abstract eligibility (see details below);
- Application for a travel grant (see details below);
- Categories (minimum 1 – maximum 3), to be selected from the "Abstract category list".
- The presenter serves as primary contact for all correspondence regarding the abstract ( except if there is a Submitter ).
- The submission of an abstract constitutes a formal commitment by the person to be in Lugano and present the abstract (if accepted) orally or as a poster. It will not be possible to contribute to the program remotely.
- The presenter may nominate a co-author to present an abstract in his/her place provided that the name of the replacement is submitted by email to firstname.lastname@example.org within 48 hours of the outcome notification.
- The presenter of a clinical abstract cannot be an employee of a pharmaceutical and/or diagnostic company. Conversely, employees of such companies may submit and present non-clinical abstracts.
Upon submission of an abstract, the presenter is responsible for the following:
- ensuring that all authors have read the abstract, agreed to be co-authors and accepted the 17-ICML submission policies and regulations;
- forwarding all correspondence regarding the abstract to all co-authors;
- releasing of the permission to live streaming, recording for multimedia coverage and including his/her presentation in the 17-ICML on-demand resources;
- disclosing any conflict of interest related to the data presented in the abstract, declaring the name of the company (s)he or any of the co-authors maintain a "relevant financial relationship" with.
“Relevant financial relationships” are intended those relationships from which the authors or any individual with whom (s)he directly shares his/her income has received or may receive financial benefit within the past 24 months.
The relationships that must be declared are: employment or leadership position in a company – consultant or advisory role - stock ownership – honoraria – research funding – travel grants – other remuneration. Unless otherwise indicated, it is implied that there are no conflicts of interests pertinent to the abstract.
- certifying that the same abstract has neither been nor will be previously published before the 17-ICML, except for Encore abstracts (abstracts presented at regional or national meetings with < 1’000 attendees, EBMT, AACR, ASCO and EHA 2023).
Encore abstracts will include the sentence “EA - previously submitted to EBMT / AACR / ASCO / EHA 2023”.
Furthermore, the presenter declares that the abstract will not be included as such in the scientific material produced in connection with any Satellite symposium held during the 17-ICML (the company organizing the Satellite symposium undertakes to verify that the abstract included in the material is formally different from the one submitted to the 17-ICML).
- declaring how the research was funded (by a pharmaceutical, biotech or other commercial company or by a Foundation or academic group) and naming the organization(s) funding the study.
Encore abstracts (EA) are accepted only if already submitted to and/or presented at:
- regional or national meetings (up to < 1’000 attendees);
- EBMT, AACR, ASCO and EHA, the large international meetings which are organized in the same period as the 17-ICML (March – July) by the European Society for Blood and Marrow Transplantation (EBMT), American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).
Encore abstracts (EA) will include the sentence “EA - previously submitted to EBMT / AACR / ASCO / EHA 2023”.
Abstracts describing trials in progress can be submitted, provided that at the time of submission the patient enrollment has already started.
No results or preliminary data must be included.
Only the scientific and clinical rationale of the trial will be evaluated.
The Ongoing trial abstracts must include only the Introduction and Methods sections.
The Ongoing Trial abstract check-box must be ticked during the submission.
The presentation format will be decided by the Organizing Committee on the basis of the evaluation results and on the Scientific Program structure.
Based on funding availability, a limited number of travel grants, sponsored by the Swiss Cancer League and possibly by other contributors, will be provided to young investigators (less than 35 years old), whose abstract has been accepted for an oral or poster presentation. The selection will be made on the basis of the abstract evaluation results.
Eligible presenters can apply for a travel grant, which is meant to cover the travel expenses to reach the 17-ICML, only at the time of the abstract submission (Travel grant check-box must be ticked).
Based on funding availability, a “merit award” will be given to the young investigator author of the highest-scoring abstract and selected for a travel grant. The recipient will receive a complimentary registration, a monetary support to attend the 17-ICML and will be recognized for his/her scientific merit in the Program Book.
Deadline: Thursday, May 25, 17:59 CEST
Late-breaking abstracts may be submitted only for studies that will have conclusive data available after the regular abstract submission deadline.
A covering letter, indicating the data expected to be available by the late-breaking abstract deadline, must be sent to email@example.com by the regular abstract deadline (March 15, 2023, 17:59 CET).
No Late-breaking abstract will be considered without the submission of the covering letter.
A member of the ICML Organizing Committee will contact the presenter to discuss the study in detail, the new research findings and implications for understanding of disease processes or clinical practice.
Only abstracts covering very high-quality research findings will be accepted and possibly included in the Late-Breaking Abstract session.
Late-breaking abstracts not selected for oral presentation will be rejected.
Min 1 – max 3
- Basic and Translational Science
- Bioinformatics; Computational and Systems Biology
- Genomics, Epigenomics, and Other -Omics
- Patient-Derived Xenograft (PDX) Models
- Risk Models
- Tumor Biology and Heterogeneity
- Cancer Health Disparities
- Diagnostic and Prognostic Biomarkers
- Experimental Therapeutics
- Cellular therapies
- Molecular Targeted Therapies
- Combination Therapies
- Radiation Therapy
- Targeting the Tumor Microenvironment
- Imaging and Early Detection
- Liquid biopsy
- Minimal residual disease
- Late Effects in Lymphoma Survivors
- Lymphoid Cancers
- Aggressive B-cell non-Hodgkin lymphoma
- Aggressive T-cell non-Hodgkin lymphoma
- Canine Lymphoma as a Surrogate
- Chronic Lymphocytic Leukemia (CLL)
- Cutaneous non-Hodgkin lymphoma
- Extranodal non-Hodgkin lymphoma
- Hodgkin lymphoma
- Indolent non-Hodgkin lymphoma
- Multiple Myeloma
- Non-Hodgkin (Pediatric, Adolescent, and Young Adult)
- Pathology and Classification of Lymphomas
- Prevention and Cancer Interception
- Therapeutics and Clinical Trials in Lymphoma
- Cellular therapies
- Molecular Targeted Therapies
- Combination Therapies
- Radiation Therapy
- Stem Cell Transplant
- Targeting the Tumor Microenvironment
- Ongoing Trials